MSD

msd.jpg

Contact information

Merck, Sharp & Dohme de España, SA (MSD)
Sara Cebrián Cuesta, Directora Asociada de Comunicación de MSD
Josefa Valcárcel, 38
Madrid
Madrid
913210600
913210700
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
      • Vaccines
    • Therapeutic areas
      • Analgesia & Pain
      • Dermatology
      • Musculoskeletal system
      • Cardiovascular diseases and circulatory system
      • Infectious diseases
      • Inflammatory diseases
      • Gynaecology and obstetrics
      • Immunology
      • Ophtalmology and optometry
      • Oncology
      • Blood and lymphatic system
      • Digestive system and hepatology
      • Central nervous system
      • Respiratory and pulmonary system
      • Metabolic disorders / Endocrinology

Today's MSD is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them.

Corporate responsibility

Corporate responsibility is our daily commitment to save and improve lives by discovering better ways to make a difference in everything we do.

http://www.merckresponsibility.com/

Products and services

MSD pipeline has over 20 promising late-stage candidates spanning the stages of life, and we have a presence in more than 100 countries around the world, including emerging markets. MSD also publishes unbiased health information as a non-profit service.

To visit MSD pipeline:
http://www.merck.com/research/pipeline/home.html?WT.svl=content
 

Areas of interest for future collaborations

Scientific discovery and development have always been the cornerstones of our company. Today, we conduct research in a broad range of therapeutic categories  including cardiovascular disease, infectious diseases, vaccines, cancer, neurology and womens health. And, to help achieve our goal of saving and improving lives around the world, we are expanding our capabilities in new areas, such as biologics.

Biotech Sanitaria

Drugs Multinational Subsidiaries
Product / Service Type Therapeutic area Development phase
ZINPLAVA Biodrugs/ Drugs Enfermedades infecciosas P III
Zilovertamab Vedotin (MK2140) Biodrugs/ Drugs Oncología P II
ZERBAXA Biodrugs/ Drugs Enfermedades infecciosas P II
ZERBAXA Biodrugs/ Drugs Sistema respiratorio y pulmonar P I
ZERBAXA Biodrugs/ Drugs Enfermedades infecciosas P I
Vericiguat Biodrugs/ Drugs Enfermedades cardiovasculares y sistema circulatorio P III
Vaxelis Vaccines Enfermedades infecciosas P III
V-937/Pembrolizumab Biodrugs/ Drugs Oncología P II
RSV vaccine Biodrugs/ Drugs Enfermedades infecciosas P III
RIG-I Biodrugs/ Drugs Oncología P I
RECARBRIO (mk7655A) Biodrugs/ Drugs Enfermedades infecciosas P III
Prevymis (Letermovir) Biodrugs/ Drugs Enfermedades infecciosas P III
Prevymis (Letermovir) Biodrugs/ Drugs Enfermedades infecciosas P III
Prevymis (Letermovir) Biodrugs/ Drugs Enfermedades infecciosas P II
Posaconazole Biodrugs/ Drugs Enfermedades infecciosas P III
Posaconazole Biodrugs/ Drugs Enfermedades infecciosas P I
Pneumococcal vaccine polyvalent Vaccines Enfermedades infecciosas P III
Pembrolizumanb/Enfortumab Biodrugs/ Drugs Oncología P III
pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib Biodrugs/ Drugs Oncología P III
Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum Biodrugs/ Drugs Oncología P II
Pembrolizumab+ MK7684 (Vibostolimab) Biodrugs/ Drugs Oncología P II
Pembrolizumab/Olaparib Biodrugs/ Drugs Oncología P III
Pembrolizumab/Olaparib Biodrugs/ Drugs Oncología P III
Pembrolizumab/Olaparib Biodrugs/ Drugs Oncología P III
Pembrolizumab/Olaparib Biodrugs/ Drugs Oncología P III